Pharma's Almanac TV
PA TV
Your Name
Your Email
Manage Account
Sign Out
Sign In
Register
Follow the Journey
Companies On The Road
Arcadis DPS Group
C2 Pharma
CAI
EcoLab
Environmental Systems Corporation
Federal Equipment Company
Globyz Biopharma Services
Grifols
Integrity
Nu-Tek BioSciences
PHARMALEX
Waters Corporation
Follow the Journey
Companies On The Road
ABS
aCGT Vector
Alconox Inc.
Andelyn Biosciences
Arranta Bio
Avid Bioservices
BDD
BIOVECTRA
DPS Group
Dynamk Capital
Environmental Systems Corporation
Federal Equipment Company
Genesis AEC
Globyz Biopharma Services
Grifols Partnership
IDT Biologika
Inceptor Bio
IPS-Integrated Project Services
Kineticos Life Sciences
MilliporeSigma
Montana BioScience Alliance
Olon
Rentschler Biopharma
SanaClis
Scorpion Biological Services
Secant Group
Tapemark
VITRONIC
Follow the Journey
Companies On The Road
AES Clean Technology
Altis Biosystems
Arranta Bio
Avara Pharmaceutical Services
Avid Bioservices
BioVectra
Centaur BPS
Dynamk Capital
ECRI
Evolve Biologics
Federal Equipment Company
Globyz
Inceptor Bio
IPS-Integrated Project Services
Olon
Pii
Polpharma Biologics
PPD
RoosterBio
SanaClis
Sanofi AIS
SGD Pharma
SPI Pharma
TriRx Pharmaceutical Services
Yourway
Dashboard
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Magazine
Archive
Reports
Nice Insight Reports
2022 Sterile
2023 Cell & Gene Therapy
2023 mAb and Recombinant Protein
2024 API
2024 OSD
2024 ADC
2024 mRNA
2024 Mammalian Cell Culture
2024 Microbial Cell Culture
2024 Plasmids
2024 Gene Therapy
2024 Cell Therapy
2024 Sterile
Community
Company A to Z
Follow the Journey
Companies On The Road
Follow The Artist
Follow the Journey
Companies On The Road
More+
Staffing
Media Kit
Bayer
24 Articles Available
Can't find what you're looking for? Try our
advanced search
.
Strategic Collaboration
Bayer and Atara Biotherapeutics Enter Strategic Collaboration for Mesothelin-Targeted CAR T-cell Therapies for Solid Tumors
PR-M11-20-030
M&A
Bayer Acquires AskBio to Broaden Innovation Base in Cell and Gene Therapy
PR-M10-20-15
CRO
Bayer and Nuvisan Create New Research Unit in Berlin
PR-M02-20-NI-013
M&A
Wuxi Biologics and Bayer Enter into an Acquisition Agreement on a Drug Product Plant in Germany
PR-M01-20-NI-025
M&A
Yellow Wood Partners to Acquire Iconic Dr. Scholl’s™ Brand from Bayer
PR-M07-19-NI-065
Recall
Bayer Statement on Voluntary Recall of Two Lots of Kogenate® FS Antihemophilic Factor (Recombinant) in the United States
PR-M07-19-NI-062
FDA Approval
FDA Approves Bayer's Gadavist® (gadobutrol) Injection as the First and Only Contrast Agent for Use in Cardiac MR for Coronary Artery Disease
PR-M07-19-NI-040
Announcement
Bayer Supervisory Board Takes Action to Address the Glyphosate Litigation and Welcomes the Appointment of Ken Feinberg as Mediator
PR-M07-19-NI-009
Collaboration
Bayer and Foundation Medicine Announce Global Collaboration to Develop Next-Generation Sequencing (NGS)-based Companion Diagnostics in Oncology
PR-M05-19-NI-078
Investment
Bayer Invests $150 Million to Build New Cell Culture Technology Center in Berkeley to Spur Innovation of Biotech Therapies
PR-M05-19-NI-040
Oncology
Bayer Announces Results of Sub-group Analysis for Vitrakvi® (larotrectinib) in Patients with NTRK Gene Fusion-Positive Metastatic Non-small Cell Lung Cancer (NSCLC)
PR-M04-19-NI-047
Corporate Culture
Bayer Only Life Science Company Named as a Most Reputable Company in Biggest-Ever Corporate Reputation Study in U.S.
PR-M04-19-NI-036
Oncology
Bayer to Obtain Full Rights to Global Development and Commercialization of Oncology Compounds Vitrakvi® (larotrectinib) and BAY 2731954 (LOXO-195)
PR-M02-19-NI-040
Veterinary
Bayer Introduces Versatile New Option for Heartworm Prevention and Intestinal Parasite Control
PR-M01-19-NI-062
Prescribing Information
Bayer Updates Betaseron (interferon beta-1b) Prescribing Information in Accordance with the U.S. Food and Drug Administration's Pregnancy and Lactation Labeling Rule
PR-M01-19-NI-004
Cutbacks and Divestitures Planned at Bayer
PAO-M12-18-NI-004
FDA Approval
FDA Approves Vitrakvi® (larotrectinib), the First Ever TRK Inhibitor, for Patients with Advanced Solid Tumors Harboring an NTRK Gene Fusion(1,2)
PR-M11-18-NI-104
Appointment
Bayer appoints Sebastian Guth to lead Pharmaceuticals business in the Americas
PR-M10-18-NI-015
Drug Development
Bayer Gets FDA Approval for Hemophilia A Drug
PAO-M09-18-NI-006
Partnership
Broad and Bayer Expand Partnership, Launching New Research Effort to Develop Therapies for Heart Failure
PR-M07-18-NI-005
Collaboration
Bayer and MD Anderson Cancer Center Collaborate to Strengthen Oncology Translational Research and Clinical Development
PR-M06-18-NI-022
Strategic Partnership
Partnerships Between Bayer and DoE Formed to Produce Radioactive Pharma Intermediate
PAO-M06-18-NI-003
Clinical Development
Evotec and Bayer Advance Third Endometriosis Programme into Phase I Clinical Development
PR-M04-18-NI-78
Clinical Data
Bayer Announces Publication of Larotrectinib Data in The New England Journal of Medicine
PR-M02-18-NI-97
.svg)